source
- BioNTech appoints Sobi head Guido Oelkers as new CEO to steer oncology shiftBioNTech announced that Guido Oelkers, who has led the rare‑disease focused Swedish company Sobi since 2017, will become its next chief executive officer. Oelkers is slated to take over the role b…
- Study Finds Accelerated Approval Rarely Used for Adult Cancer Drugs Over Past 20 YearsA new analysis published in JAMA shows that most adult oncology medicines approved by the FDA in the last two decades received standard approvals for expanded uses, relying on surrogate endpoints r…